Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

After years of research into xenotransplantation, the field is at a turning point—yet risks and ethical issues remain ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside ...

CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

The global Biologics Industry was valued at US$ 515.6 billion in 2022 and is projected to grow at a CAGR of 6.9% from 2023 to ...